Immunotherapies such as immune checkpoint blockade (ICB) and adoptive cell therapy
(ACT) have revolutionized cancer treatment, especially in patients whose disease was …

Dysregulation of the epigenome drives aberrant transcriptional programmes that promote
cancer onset and progression. Although defective gene regulation often affects oncogenic …

Therapeutic monoclonal antibodies targeting immune checkpoints (ICPs) have changed the
treatment landscape of many tumors. However, response rate remains relatively low in most …

The interplay between an evolving cancer and a dynamic immune microenvironment
remains unclear. Here we analyse 258 regions from 88 early-stage, untreated non-small-cell …

Background Advanced recurrent ovarian cancer (ROC) is the leading cause of gynecologic
cancer-related death in developed countries and new treatments are needed. Previous …

Cancer is a leading cause of death worldwide and, despite new targeted therapies and
immunotherapies, many patients with advanced-stage-or high-risk cancers still die, owing to …

Tumor neoantigen is the truly foreign protein and entirely absent from normal human
organs/tissues. It could be specifically recognized by neoantigen-specific T cell receptors …

Growing evidence suggests that aberrant epigenetic regulation of gene function is strongly
related to the genesis of cancer. Unlike genetic mutations, the ability to reprogram the …

Purpose: The tumor microenvironment (TME) consists of a heterogenous cellular milieu that
can influence cancer cell behavior. Its characteristics have an impact on treatments such as …

Chemokines are small secreted proteins that orchestrate migration and positioning of
immune cells within the tissues. Chemokines are essential for the function of the immune …